Home / People / Jean-Baptiste Thiénot
Portrait of Jean-Baptiste Thiénot

Jean-Baptiste Thiénot


CMS Francis Lefebvre Avocats
2 rue Ancelle
92522 Neuilly-sur-Seine
Languages English, French, German

Jean-Baptiste Thiénot is Partner in the IP/IT team of CMS Francis Lefebvre. He mainly advises on industrial property law, particularly patent law.

His activity covers litigation (infringement and nullity actions, employee invention issues) as well as advice and drafting of contracts (R&D contracts, assignment and licensing, audit of rights portfolio) in various industrial sectors, particularly in the life sciences, mechanical and electronic fields. He is frequently involved in cases relating to products subject to specific regulations (health products, cosmetics, spraying, etc.).

Jean-Baptiste has also developed a particular expertise in the protection of business secrets/know-how (litigation, implementation of internal protection policies) and the regulation of health products (medicines, medical devices, etc.). He advises manufacturers in the health sector on their innovative projects, particularly in relation to e-health (telemedicine) and the compliance of their practices ("anti-gift" and "transparency" laws).

Jean-Baptiste Thiénot has been a lawyer since 2008. He joined CMS Francis Lefebvre in 2018 after practising with the law firms Simmons & Simmons (2008-2011), Allen & Overy (2011-2013) and Bird & Bird (2013-2018).

more less

Intellectual property: Patents

Legal 500 EMEA 2021

Industry focus: Healthcare and Life sciences

Legal 500 EMEA 2019

Intellectual Property : Patents

Legal 500 EMEA 2020

Propriété Intellectuelle : Brevets

Legal 500 EMEA 2020

Memberships & Roles

  • Member of LES, APRAM and AIPPI
  • Member of Carré des juristes de France Biotech
  • Member of Bar Hauts-de-Seine
more less


  • « Secondes applications thérapeutiques : la décision « SANTEN » rebat les cartes »- La Lettre PI (february 2021)
  • « Action en nullité de brevet : la démonstration de l’intérêt à agir » - La Lettre PI (january 2021)
  • « Mouvements de salariés et protection des informations confidentielles de l’entreprise » - La lettre des fusions acquisitions et du private equity (Option Finance) (december 2020)
  • « Dernières actualités concernant le dispositif « anti-cadeaux »» - LinkedIn (november 2020)
  • « MSD’s ezetimibe-simvastatin SCP revoked by the Paris Court of Appeal » - The SPC Blog (october 2020)
  • « Réforme anti-cadeaux : quelles actions mettre en place ? » - LinkedIn (september 2020)
  • « Vers une responsabilité accrue des plateformes numériques dans la lutte contre la contrefaçon ? » - La Lettre PI (april 2020)
  • Propriété intellectuelle et opération de fusion acquisition : préférez une revue sur mesure » - La lettre des fusions acquisitions et du private equity - Option Finance (march 2020)
  • « Le renouveau des interdictions provisoires (preliminary injunctions) » – Bulletin rapide de droit des affaires (BRDA) (march 2020)
  • Recent changes in patent law” - LinkedIn (march 2020)
  • « les risques inhérents à l’exécution de mesures provisoires ; CJUE, 12 septembre 2019, C-688/17 » – lettre PI (december 2019)
  • « La brevetabilité des procédés de présentation d’information : à propos des méthodes d’affichage facilitant la recherche et la navigation - TGI Paris, 11 juillet 2019, n° 16/02073 » – lettre PI (december 2019)
  • « La fiscalité avantageuse des revenus des actifs de propriété industrielle » - La lettre des fusions acquisitions et du private equity - co-auteru -  Option Finance (october 2019)
  •  “The interpretation and application of the doctrine of equivalence - Actavis v Eli Lilly 2 years on” co-écrit avec Caitlin Heard et Thomas Hirse, The Patent Lawyer (october 2019)
  • « Cannabis : a legal guide” – co-écrit avec les autres bureaux CMS (june 2019)
  • « Loi PACTE : analyse des nouveautés en droits de la propriété industrielle » - La lettre des fusions acquisitions et du private equity (Option Finance) (mai 2019)
  • « L’inventeur, l’employeur et les autres » - Dalloz IP-IT (march 2019)
  • « Pas de certificat complémentaire de protection pour un dispositif médical incorporant un produit pharmaceutique » - Lettre PI (january 2019)
more less


  • Master II « droit de la propriété littéraire et artistique », Université Paris II–Assas dirigé par Pierre-Yves Gautier (2005)
  • CAPA (2008)
more less


Phar­ma­ceut­ic­al ad­vert­ising reg­u­la­tion and med­ic­al device ad­vert­ising in...
Rules ap­plic­able to the ad­vert­ising of veter­in­ary medi­cines are not ad­dressed in this ques­tion­naire. 1. Which laws are ap­plic­able re­gard­ing ad­vert­ising of medi­cines and med­ic­al devices? 1.1 Medi­cines...
Can­nabis law and le­gis­la­tion in France
Med­ic­al use In prin­ciple, pur­su­ant to Art­icle R. 5132-86-1 of the French Pub­lic Health Code (PHC), the cul­ture, man­u­fac­ture, trans­port, im­port, ex­port, hold­ing, of­fer, trans­fer, ac­quis­i­tion and use of...
Glob­al LSHC For­um 2022
Un­cer­tain times, an evolving leg­al frame­work: man­aging risks and en­sur­ing so­cial re­spons­ib­il­ity in the life sci­ences & health­care sec­tor
Ad­verse ef­fects of drugs and vac­cines in France
1. Drug ad­verse ef­fects: kinds of re­spons­ib­il­ity 1.1 Which are the main kinds of re­spons­ib­il­ity (con­trac­tu­al, in tort, crim­in­al) of the fol­low­ing sub­jects with re­spect to ad­verse drugs re­ac­tions? A. ...
Trade secret laws and reg­u­la­tions in France
Gen­er­al 1. Has the Dir­ect­ive (EU) 2016/943 of the European Par­lia­ment and of the Coun­cil of 8 June 2016 on the pro­tec­tion of un­dis­closed know-how and busi­ness in­form­a­tion (trade secrets) against their...
LEG­AL 500 EMEA 2022
The 2022 edi­tion of the Leg­al 500 EMEA guide is out. We would par­tic­u­larly like to thank our cli­ents for put­ting their trust in us! Our law firm’s rank­ings in France, Al­ger­ia and Mo­rocco France...
Re­form of the re­gime for in­ven­tions and soft­ware of non-em­ploy­ees col­lab­or­at­ors
The French In­tel­lec­tu­al Prop­erty Code (IPC) provides, un­der cer­tain con­di­tions, for an auto­mat­ic vest­ing in the em­ploy­er of in­tel­lec­tu­al prop­erty rights on in­ven­tions and soft­ware of em­ploy­ees and pub­lic...
CBD and hemp flowers
While the trade in products con­tain­ing can­na­bi­d­i­ol (CBD) is vis­ibly in­creas­ing (in cos­met­ics, vap­ing products, raw leaves and flowers, etc.), the French law ap­plic­able to this activ­ity is not yet fixed...
Vac­cine com­pens­a­tion re­gimes in France
1. Are COV­ID-19 vac­cin­a­tions ob­lig­at­ory in your jur­is­dic­tion? Are you ex­pect­ing any le­gis­lat­ive changes to en­able man­dat­ory vac­cines for all or cer­tain people (e.g. health­care pro­fes­sion­als, pub­lic ser­vants...
Trans­fer of IP rights in France
Pat­ents: As­sign­ment 1. How may a pat­ent be as­signed (by law and/or trans­ac­tion) and is it re­quired to re­cord the as­sign­ment in the na­tion­al pat­ent re­gister to be­come ef­fect­ive?  To trans­fer a pat­ent...
Com­puls­ory li­cens­ing in France
1. What is the defin­i­tion of com­puls­ory li­cens­ing? Com­puls­ory li­cens­ing refers to a leg­al mech­an­ism by which a ju­di­cial court or the gov­ern­ment grants a third party with a li­cence, without the pri­or...
Di­git­al health apps and telemedi­cine in France
Di­git­al Health Apps/Soft­ware 1. How is the soft­ware with­in di­git­al health apps clas­si­fied in your jur­is­dic­tion, and what reg­u­la­tion(s) ap­ply? 1.1 Is it con­sidered a “med­ic­al device” or a “product”...